https://mc06.manuscriptcentral.com/apnm-pubs Methods: Two single nucleotide polymorphisms (SNPs) (rs1527479 and rs1984112) were assessed for 28 associations with whole-body substrate oxidation, response to a 75g dextrose oral glucose tolerance test 29 (OGTT), fasting plasma lipids and CVD risk factors in a young healthy cohort, both using cross-sectional 30 analysis and following a 4-week endurance exercise training program. Genotyping was performed using 31
Introduction:
49 Long-chain fatty acids (LCFAs) are the predominant substrate source for ATP re-synthesis both at rest, 50 and during light to moderate exercise in healthy individuals. Fatty acid translocase (FAT)/cluster of 51 differentiation 36 (CD36) is a multifunctional 88kDa glycoprotein that has been shown to be the 52 predominant transporter in the highly regulated process by which LCFAs are transported from adipose 53 tissue into the heart and skeletal muscle cells, as well as the mitochondria (Ibrahimi et al. 1999; Bonen et 54 al. 2007; Yanai et al. 2007; Nickerson et al. 2009 ). CD36 is unique, as it is the only identified fatty acid 55 (FA) transport protein that modulates lipid uptake across the sarcolemma and into the mitochondria 56 (Bezaire et al. 2006; Holloway et al. 2006; Smith et al. 2012) , particularly during muscle contraction. 57
Gene variants within the CD36 gene have previously been associated with multiple metabolic health 58 indicators related to cardiovascular disease (CVD) (Lepretre et al. 2004; Ma et al. 2004; Febbraio and 59 Silverstein 2007; Noel et al. 2010) , highlighting a pleiotropic influence. Moreover, particular single 60 nucleotide polymorphisms (SNPs) within the CD36 gene have also been directly associated with 61 metabolic conditions, such as type II diabetes mellitus (T2DM), in older cohorts (Corpeleijn et al. 2006) . which participants trained was determined, relative to their initial VO 2peak and increased incrementally 186 over the 4 week training period such that participants cycled at 60% VO 2peak for weeks 1 and 2, 70% 187 VO 2peak for week 3and 75% VO 2peak for week 4. Participants were instructed to maintain pre-study dietary 188 and habitual PA patterns over the course of the training intervention. 189
190

SNP Genotyping
191
Genomic DNA was extracted from peripheral whole blood using a Promega wizard® genomic DNA 192 purification kit (Promega, Madison, WI, USA). Genotyping of SNP rs1527479 in the upstream promoter 193 region (intron 1B, -3489 bp relative to the translation start site), as well as SNP rs1984112 (5' flanking 194 exon 1A, -33137 bp relative to the translation start site) were performed using custom Taqman® 
Statistical Analyses
214
All data were assessed for normality using histograms and descriptive statistics. Normally distributed data 215 are presented as Mean ± SD. Non-normally distributed data were log transformed prior to use in 216 parametric statistics if possible and presented as median (range). Both SNP loci were tested for departure 217 from Hardy -Weinberg equilibrium using a Chi-square (χ 2 ) analysis. Baseline data was analysed using 218 sequential one-way Analysis of Covariance (ANCOVA). Dominant-allele analyses were also performed 219 (SNP carriers vs. non-carriers) on baseline data and used to assess all training outcomes, due to the 220 limited sample size and adequate distribution amongst genotypes. Cross-sectional data 238 TT carriers of rs1527479 had significantly greater Fat ox compared to C-Allele carriers at 40% VO 2peak (P 239 = 0.033; g = -0.8) and tended towards higher Fat ox at 60% (P = 0.061; g = -0.5) (Figure 1(a) ). No 240 difference was observed in Fat ox during dominant model analysis of the screening data at rs1984112 (P > 241 0.05) (Figure 1(c) ). 242 243 At rs1527479, the TT genotype tended towards being greater at fasting blood glucose (FBG) (P = 0.066; 244 g = -0.5) ( Table 1 ). Genotypic variation in the cross-sectional TG screening data at rs1984112 was 245 present, with AA carriers significantly greater than G-allele carriers (P = 0.01; g = -0.9) ( Table 1) . No 246 other significant differences were evident in OGTT and fasting plasma lipid markers at baseline (P > 247 0.05; Figure 2 (Table 2) . Post-training assessment showed that TT carriers also 264 experienced a decrease in TG levels compared to C-Allele carriers (P gxt = 0.009; g = 1.1) ( Table 2 ). At 265 SNP rs1984112, a significant genotype x time interaction was present in HDL-C (P gxt = 0.024) ( Table 3) . and/or abundance, depending on the location and influence of the SNP. This could be a possible 285 mechanism behind the previously mentioned associations between the CD36 SNPs investigated in our 286 research and chronic disease states and risk factors identified in older cohorts (Ma et al. 2004; Corpeleijn 287 et al. 2006; Rodrigues et al. 2013) . Whilst significant differences in Fat ox were evident during cross-288 sectional analysis at stage 1 using both models of analysis at both SNPs, only analysis at rs1984112 was 289 consistent with our hypothesis, with the GG WT genotype exhibiting higher Fat ox at 20 -40% VO 2peak 290 (Supplementary Table S2) . 291 292 When training data were analysed using the dominant model at both SNPs, a gene-exercise interaction 293 effect was only evident at rs1984112 at rest. Additional analysis performed in an attempt to possibly 294 reduce the confounding influence of the alternate SNP strengthened this association (P gxt = 0.001, 295
Supplementary Table S11). A similar analysis on SNP rs1527479 data also observed a significant 296 D r a f t 14 genotype x time interaction at resting Fat ox (P gxt = 0.414 to P gxt = 0.012). Large effect sizes were also 297 present at both SNPs (|g| = 0.6 -1.1). Significant increases in Fat ox were evident as a result of the training 298 program prior to covariate adjustment, predominantly present at training specific exercise intensities (50 -299 70% VO 2peak ). With CHO ox decreasing across all intensities at both SNPs, our data is consistent with the 300 notion that there is a preferential switch to fat oxidation following endurance training. Research 301 investigating the ameliorating effects of exercise training on metabolic impairments, such as FA 302 accumulation, as a result of genetic factors in rat models showed that the influence of selective breeding 303 resulting in reduced expression of a number of key metabolic genes could be overturned as a result of Cross-sectional assessment between participants in the present study observed that AA SNP carriers at 311 rs1984112 had significantly elevated TG, an association reinforced following the addition of rs1527479 312 as a covariate in ANCOVA model (P = 0.008, Supplementary Table S10). Ma and colleagues (2004) 313 identified a haplotype, including SNP rs1984112, which was associated with not only elevated TG, but 314 also free-fatty acids (FFA) (Ma et al. 2004) . With the authors suggesting their results were consistent with 315 those seen in CD36 knockout mouse models (Febbraio et al. 1999) , they postulate that the increased 316 plasma FFA associated with decreased clearance, as a result of decreased CD36 expression, would lead to 317 increased hepatic FFA uptake, leading to increased production of TGs. Unfortunately, FFA was not 318 collected in the present study to test whether this hypothesis was present, but its inclusion for analysis in 319 future work would be of great interest. However, the association evident in our pre-clinical cohort is ofD r a f t great interest, particularly with the documented importance of TGs as a biomarker for CVD risk and all-321 cause mortality (Miller et al. 2011; Nordestgaard and Varbo 2014) . 322 323 Specificity in prescribing interventions aimed at reducing such CVD risk factors requires further 324 investigation. A significant gene-exercise interaction was evident in our data at rs1527479, with the high-325 risk TT genotype group exhibiting a protective reduction in TG following exercise-training when 326 compared to C-allele carriers, an interaction present independent of SNP rs1984112. Previous research 327 investigating the effect of exercise-training on TG levels suggest that in the absence of concurrent weight-328 loss and/or reduced energy intake (Duncan et al. 2005; Fontana et al. 2007) , there would be a minimal 329 reduction in plasma TGs, whilst elevated baseline TG level (>1.69 mmol/L) was also a determining factor 330 (Durstine et al. 2002) . In the present data, baseline grouped means were below this range, participants 331
were instructed not to alter dietary patterns over the course of the intervention and no significant 332 difference in weight loss between these groups were identified. With these factors considered, the 333 genotype x time interactions evident could well be related to the impact of the training stimulus on CD36 334 protein function and/or abundance. Further investigation of this potential protective gene-exercise 335 interaction on plasma TG is warranted and required to make any significant and appropriate interpretation 336 of this data however, with the greater control of diet via meal provisions throughout the training 337 intervention merited, in order to ensure there would be no increase in caloric intake often associated with 338 exercise (Laan et al. 2010) . 339 340 Whilst no significant difference in BP measures were evident in the present cross-sectional and baseline 341 data, significant genotype x time interactions were present at both SNP loci in our training data. Rice and 342 colleagues (2002) investigated heritability of HR and BP response to exercise training in the HERITAGE 343 family cohort (Rice et al. 2002) . Following a 20-week exercise-training program, they reported that the 344 trainability of SBP in hypertensive families appears to be determined by genetic factors, this observationD r a f t was not present in the normotensive sub-group, whilst DBP response was believed to be a result of 346 environmental factors as opposed to genetic. In our cohort, DBP and MAP values at rs1527479 exhibited 347 favourable adaptation for TT carriers when compared to C-allele carriers (g = 0.9 and g = 0.8, 348 respectively), opposing our hypothesis that this "at-risk" group would not respond as well. DBP and MAP 349 response when participants were stratified at rs1984112 were not expected, with an increase in DBP in 350 both G-allele and AA groups, whilst AA carriers increased MAP and no change was seen in the G-allele The variance in Fat ox identified at stage 1 analysis at both SNP loci in the present study were contrary to 365 previous cross-sectional pilot data collected by this lab in a separate study cohort (Jayewardene et al. 366 2014), where C-allele carriers at rs1527479 shown to have elevated Fat ox when compared to TT carriers, 367 and no difference evident at SNP rs1984112 in that particular data set. As we investigated similar 368 associations in a slightly larger cohort, with the only change being a shift towards lower exercise 369 intensities, due to potential inaccuracies associated with higher exercise intensities (Jeukendrup andD r a f t associations present within our cohort (comparisons presented in Table 4 ). 372
373
Of the significant genotype x time interactions identified in our stage 2 data, a number of the more 374 favourable responses to the training program were present in the "at-risk" genotypes for Fat ox , TG, and 375 BP variables between both SNPs. Whilst these findings are not consistent with our hypothesis, it may 376 suggest that these particular individuals may have a greater capacity for positive metabolic flexibility 377 when an external stimuli is exerted. The implications of this theory are that the adverse associations 378 Note: Data presented as means ± SDs. Non-normally distributed data presented as median (range). BMI, body mass index; WC, waist 595 circumference; HC, hip circumference; WHR, waist-to-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial 596 pressure; RHR, resting heart rate; RPP, rate-pressure product; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-597 density lipoprotein cholesterol; TG, triglyceride; FBG, fasting blood glucose; BG 120 , blood glucose at 120-min of the OGTT; VO 2peak , peak 598 oxidative capacity; W peak , peak power output; Fat ox0 , whole body fat oxidation rate at rest. a Metabolite readings outside the range of the 599 CardioChek® analyser were entered as the closest limit value for the respective assay. D r a f t 
